Blood Plasma Market Share, Size, Trends, Industry Analysis Report, By Type (Albumin, Factor VIII, Factor IX, Immunoglobulin, Hyperimmune Globulin, Others); By Application; By End-Use; By Region; Segment Forecast, 2023- 2032

Blood Plasma Market Share, Size, Trends, Industry Analysis Report, By Type (Albumin, Factor VIII, Factor IX, Immunoglobulin, Hyperimmune Globulin, Others); By Application; By End-Use; By Region; Segment Forecast, 2023- 2032

The global blood plasma market size is expected to reach USD 54,787.67 million by 2032, according to a new study by Polaris Market Research. The report “Blood Plasma Market Share, Size, Trends, Industry Analysis Report, By Type (Albumin, Factor VIII, Factor IX, Immunoglobulin, Hyperimmune Globulin, Others); By Application; By End-Use; By Region; Segment Forecast, 2023- 2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The blood plasma market is experiencing substantial growth due to the increasing prevalence of severe blood disorders, notably Hemophilia and Thalassemia, impacting hundreds of newborns annually. Blood plasma, the fluid component of blood, plays a crucial role in transporting various blood constituents and is particularly in demand from individuals with blood type A.B. It is used in treating burn, shock, trauma, and clotting disorders, aiding in blood volume, shock prevention, and clotting support. Pharmaceutical companies utilize plasma for producing treatments for bleeding disorders and immune deficiencies.

The market's expansion is driven by government initiatives, growing public awareness, research and development efforts, healthcare sector expansion, an aging population, and increased adoption of plasma-derived products. Plasma-derived products like coagulation factor VIII and immunoglobulins are essential for managing blood-related disorders. Research and development in advanced plasma-derived products, strategic manufacturing, technological advancements, a substantial patient base, and increased healthcare expenditure all contribute to the market's positive trajectory during the 2022 to 2032 forecast period.

The blood plasma market faces disruption from recombinant alternatives that offer treatments for various medical conditions without relying on human plasma. Biologically engineered proteins and clotting factors can be produced through recombinant technologies, reducing dependence on plasma. This competition can impact pricing and market share, as recombinant alternatives are perceived as safer, eliminating the risk of pathogen transmission associated with plasma-derived products in specific diseases and medical conditions.

Blood Plasma Market Report Highlights

Immunoglobulins dominated with 45.4% revenue share in 2022, serving vital roles in immune responses and treating autoimmune and immunodeficiency disorders.

Immunodeficiency Diseases segment accounted for 28.7% of revenue in 2022, primarily relying on blood plasma-derived products, like immunoglobulins, to manage various primary immunodeficiency disorders.

North America led the 2022 global market 45.5% share in supplying plasma-derived products, vital for international demand and public health preparedness.

The global key market players include Biotest AG, CSL, GC Biopharma Corp, Grifols, Intas Pharmaceuticals Ltd, Kedrion S.p.A., LFB, Octapharma AG, Sanquin, Takeda Pharmaceuticals

Polaris Market Research has segmented the Blood Plasma market report based on Type, Application, End-User, and region:

Blood Plasma, Type Outlook (Revenue - USD Million, 2019 - 2032)

Albumin

Factor VIII

Factor IX

Immunoglobulin

Hyperimmune Globulin

Others

Blood Plasma, Application Outlook (Revenue - USD Million, 2019 - 2032)

Hemophilia

Hypogammaglobinemia

Immunodeficiency Diseases

Von Willebrand’s Disease

Others

Blood Plasma, End-User Outlook (Revenue - USD Million, 2019 - 2032)

Hospitals

Clinics

Others

Blood Plasma, Regional Outlook (Revenue - USD Million, 2019 - 2032)

North America

U.S.

Canada

Europe

Germany

UK

France

Italy

Spain

Russia

Netherlands

Asia Pacific

China

India

Japan

South Korea

Indonesia

Malaysia

Latin America

Argentina

Brazil

Mexico

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa